DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties

Development of novel bioactive compounds against KRAS and/or BRAF mutant colorectal cancer (CRC) is currently an urgent need in oncology. In addition, single or multitarget kinase inhibitors against MEK/ERK and PI3K/AKT pathways are of potential therapeutic advantage. A new compound based on the ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Goulielmaki, Maria, Assimomytis, Nikos, Rozanc, Jan, Taki, Eleni, Christodoulou, Ioannis, Alexopoulos, Leonidas G., Zoumpourlis, Vassilis, Pintzas, Alexandros, Papahatjis, Demetris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520640/
https://www.ncbi.nlm.nih.gov/pubmed/31096110
http://dx.doi.org/10.1016/j.tranon.2019.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520640/
https://www.ncbi.nlm.nih.gov/pubmed/31096110
http://dx.doi.org/10.1016/j.tranon.2019.04.005

Ejemplares similares